Surgery

Artes Medical Announces Enrollment of First Patient in 1000 Patient Post-Marketing ArteFill Study for Treatment of Smile Line Wrinkles

Published in Drug Week, October 19th, 2007

Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, announced that treatment has started in a new 1000-patient post-marketing study that will follow patients treated with the Company's FDA-approved non-resorbable dermal filler, ArteFill(R), for a period of five years.

Study participants will receive ArteFill injections into their facial wrinkles, known as nasolabial folds or smile lines, at up to twenty-five leading Dermatology and Plastic Surgery centers throughout the United States and Canada. The co-lead investigators are Steven R....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry